Matsui T - Search Results

1

Advanced glycation end products, oxidative stress and diabetic nephropathy.

Yamagishi S, Matsui T. Yamagishi S, et al. Among authors: matsui t. Oxid Med Cell Longev. 2010 Mar-Apr;3(2):101-8. doi: 10.4161/oxim.3.2.11148. Oxid Med Cell Longev. 2010. PMID: 20716934 Free PMC article. Review.

2

Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression.

Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H. Yamagishi S, et al. Among authors: matsui t. FEBS Lett. 2005 Aug 15;579(20):4265-70. doi: 10.1016/j.febslet.2005.06.058. FEBS Lett. 2005. PMID: 16051229

3

Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.

Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Yamagishi S, et al. Among authors: matsui t. Med Hypotheses. 2006;66(5):1019-21. doi: 10.1016/j.mehy.2005.08.023. Epub 2005 Sep 26. Med Hypotheses. 2006. PMID: 16188392

4

Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.

Yamagishi S, Nakamura K, Matsui T, Takeuchi M. Yamagishi S, et al. Among authors: matsui t. Med Hypotheses. 2006;66(2):273-5. doi: 10.1016/j.mehy.2005.08.042. Epub 2005 Oct 10. Med Hypotheses. 2006. PMID: 16216433

5

Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.

Nakamura K, Yamagishi S, Matsui T, Inoue H. Nakamura K, et al. Among authors: matsui t. Drugs Exp Clin Res. 2005;31(4):155-9. Drugs Exp Clin Res. 2005. PMID: 16223205

6

Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.

Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y, Imaizumi T. Nakamura K, et al. Among authors: matsui t. Microvasc Res. 2005 Nov;70(3):137-41. doi: 10.1016/j.mvr.2005.10.002. Microvasc Res. 2005. PMID: 16271939

7

Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.

Matsui T, Yamagishi S, Nakamura K, Kikuchi S, Inoue H. Matsui T, et al. Drugs Exp Clin Res. 2005;31(5-6):215-9. Drugs Exp Clin Res. 2005. PMID: 16425978

8

Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells.

Yamagishi S, Matsui T, Inoue H. Yamagishi S, et al. Among authors: matsui t. Drugs Exp Clin Res. 2005;31(5-6):227-32. Drugs Exp Clin Res. 2005. PMID: 16425980

9

Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.

Yamagishi S, Matsui T, Nakamura K, Takeuchi M. Yamagishi S, et al. Among authors: matsui t. Int J Tissue React. 2005;27(4):189-95. Int J Tissue React. 2005. PMID: 16440584

10

Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy.

Yamagishi S, Matsui T, Nakamura K, Inoue H. Yamagishi S, et al. Among authors: matsui t. Int J Tissue React. 2005;27(4):197-202. Int J Tissue React. 2005. PMID: 16440585

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results